Anocca is a corporate office located in Södertälje that specializes in precision T-cell immunotherapies. The organization focuses on engineering T-cell receptor (TCR) therapies aimed at treating untreatable cancers. By combining novel T-cell biology with advanced biotechnologies, Anocca seeks to develop innovative solutions for cancer treatment.
The company utilizes integrated software to enhance the development of its therapies, which supports its commitment to improving patient outcomes. Anocca is actively developing a diverse pipeline of immunotherapy options, emphasizing a scientific approach to cancer immunology. Through its research and development efforts, the organization aims to provide tailored therapies that address the specific needs of patients facing challenging cancer diagnoses.